Infex Therapeutics Advances RESP-X Toward Next-Stage Development
ALDERLEY PARK, Cheshire, U.K. — September 8, 2026 Infex Therapeutics presented new data from its Phase IIa study of...
respiratory diseases
Advertisement
Upstream Bio Advances Verekitug Toward Phase 3 in Asthma
WALTHAM, Mass. — September 8, 2026 Upstream Bio, Inc. presented results from the Phase 2 VALIANT trial of verekitug...
Upstream Bio Sets Phase 3 Plans for Verekitug in Asthma
WALTHAM, Mass., Sept. 1, 2026 Upstream Bio, Inc. has announced its pivotal Phase 3 development plans for verekitug in...
ArkBio Advances Ziresovir in FDA-Approved Phase II RSV Trial
Shanghai, China, August 14, 2026 Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announced that the U.S. Food and Drug Administration...
ArkBio Advances AK0406 with China IND Approval
Shanghai, China, August 12, 2026 Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announced that China’s National Medical Products Administration (NMPA)...
Advertisements
Bambusa Reports Promising BBT002 Data for COPD Therapy
BOSTON, June 15, 2026 Bambusa Therapeutics has announced positive preliminary multiple ascending dose (MAD) Phase 1 clinical data for...
Bambusa Therapeutics Reports Positive Phase 1 BBT002 Data at EAACI 2026
BOSTON, June 15, 2026 Bambusa Therapeutics has announced positive preliminary results from the multiple ascending dose (MAD) cohorts of...
Insmed Unveils Phase 3 ARIKAYCE Data at ATS 2026
BRIDGEWATER, NEW JERSEY, May 04, 2026 Insmed Incorporated has announced the presentation of multiple clinical and real-world data sets...
ArkBio Advances AK0406 Phase I Trial for Influenza
SHANGHAI, April 10, 2026 Shanghai Ark Biopharmaceutical Co., Ltd. has announced a key clinical milestone with the successful dosing...
GSK Secures China Approval for Exdensur in Nasal Polyps Treatment
LONDON, UK, April 8, 2026 GSK has announced that China’s National Medical Products Administration (NMPA) has approved Exdensur (depemokimab),...
Advertisement
